0001567619-21-012329.txt : 20210617
0001567619-21-012329.hdr.sgml : 20210617
20210617163214
ACCESSION NUMBER: 0001567619-21-012329
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210615
FILED AS OF DATE: 20210617
DATE AS OF CHANGE: 20210617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jacobs Jeffrey W
CENTRAL INDEX KEY: 0001611193
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36485
FILM NUMBER: 211025162
MAIL ADDRESS:
STREET 1: C/O ARDELYX, INC.
STREET 2: 34175 ARDENWOOD BLVD, SUITE 100
CITY: FREMONT
STATE: CA
ZIP: 94555
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARDELYX, INC.
CENTRAL INDEX KEY: 0001437402
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 34175 ARDENWOOD BLVD.
CITY: FREMONT
STATE: CA
ZIP: 94555
BUSINESS PHONE: 510-745-7047
MAIL ADDRESS:
STREET 1: 34175 ARDENWOOD BLVD.
CITY: FREMONT
STATE: CA
ZIP: 94555
FORMER COMPANY:
FORMER CONFORMED NAME: NTERYX INC
DATE OF NAME CHANGE: 20080611
4
1
doc1.xml
FORM 4
X0306
4
2021-06-15
0
0001437402
ARDELYX, INC.
ARDX
0001611193
Jacobs Jeffrey W
C/O ARDELYX, INC.
34175 ARDENWOOD BLVD, SUITE 200
FREMONT
CA
94555
0
1
0
0
Chief Scientific Officer
Common Stock
2021-06-15
4
M
0
7500
0.54
A
131551
D
Common Stock
2021-06-15
4
S
0
7500
7.2878
D
124051
D
Stock Option (Right to Buy)
0.54
2021-06-15
4
M
0
7500
0.00
D
2021-08-11
Common Stock
7500
10000
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 10, 2021.
This transaction was executed in multiple trades in prices ranging from $7.242 to $7.41, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The option, which was granted on August 11, 2011 and has an expiration date of August 11, 2021, is fully vested and exercisable.
/s/ Elizabeth Grammer, Attorney-in-Fact for Jeffrey W. Jacobs
2021-06-17